May 2014, Vol 3, No 3

← Back to Issue

The Full Spectrum of Knowledge Driving Personalized Medicine

Darren Sigal, MD

Letter to Our Readers

Dear Colleague,

One of the fascinating aspects of personalized medicine is the recognition of how each component relates to all other components. Take this month’s “The Last Word” column, where one of healthcare’s premier policy authorities, Kip Piper, weighs in on the impact of the Affordable Care Act on cancer care in this second of a 2-part series. This leads us to reflect on the practical reality of healthcare’s triad of medical, business, and policy forces, intertwined and influencing the process of care. The editors of Personalized Medicine in Oncology (PMO) make certain to bring the whole picture of this process to practicing oncologists:

  • The clinical needs driving drug and device utilization
  • The business and policy context influencing clinical practice
  • The winners and losers in the wake of healthcare reform
  • Clarity of treatment options in a healthcare system undergoing a paradigm shift

Knowledge is power, and PMO is dedicated to increasing oncologists’ power to heal in this changing paradigm. The extraordinary variety of knowledge we organize for our readers helps bridge the gap from drug discovery to real-world practice. We are pleased to have you in our reading community as we open the door to the full spectrum of knowledge driving personalized medicine in cancer.

Sincerely,

Darren Sigal, MD
Scripps Clinic
PMO Board Member

Uncategorized - May 15, 2014

The Affordable Care Act: Where Are We Now, What’s the Future?

The Affordable Care Act (ACA) is in its infancy, but it is already changing oncology practice, said panelists during a roundtable discussion at the 2014 meeting of the National Comprehensive Cancer Network (NCCN). The changing composition of oncology patients, the risk pool of the exchanges, new payment and reimbursement models, [ Read More ]

Uncategorized - May 16, 2014

Investigational Angiogenesis Inhibitor Improves Survival as Second-Line Treatment in Gastric Cancer

Phase 3 data from a global study indicated an improvement in overall survival (OS) when the investigational angiogenesis inhibitor ramucirumab was added to chemotherapy as second-line therapy in patients with advanced gastric cancer. The improvement in survival was more than 2 months with ramucirumab when used after progression on first-line [ Read More ]